SoftMedx Healthcare Limited has published its audited financial results for the year ended 31 December 2024. The company reported a 6.4% increase in revenue, reaching HK$54.6 million, compared to HK$51.3 million in the previous year. This growth was primarily driven by the company's efforts to expand its product offerings by obtaining new product sources. Despite facing challenges from shifting consumer preferences and competitive market conditions, SoftMedx managed to increase its sales volume and maintain its market position. The company continues to focus on leveraging its industry expertise and customer relationships to deliver high-quality healthcare products and services. Trading in the company's shares remains suspended pending the fulfillment of resumption conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.